Table of Content

1 Tumour Neoantigens Market Overview
1.1 Product Overview and Scope of Tumour Neoantigens
1.2 Tumour Neoantigens Segment by Type
1.2.1 Global Tumour Neoantigens Market Value Comparison by Type (2024-2034)
1.2.2 Common Neoantigens
1.2.3 Individualized Neoantigens
1.3 Tumour Neoantigens Segment by Application
1.3.1 Global Tumour Neoantigens Market Value by Application: (2024-2034)
1.3.2 T Cell Adoptive Therapy
1.3.3 DC Therapy
1.3.4 Therapeutic Vaccines
1.3.5 Other
1.4 Global Tumour Neoantigens Market Size Estimates and Forecasts
1.4.1 Global Tumour Neoantigens Revenue 2024-2034
1.4.2 Global Tumour Neoantigens Sales 2024-2034
1.4.3 Global Tumour Neoantigens Market Average Price (2024-2034)
1.5 Assumptions and Limitations
2 Tumour Neoantigens Market Competition by Manufacturers
2.1 Global Tumour Neoantigens Sales Market Share by Manufacturers (2024-2024)
2.2 Global Tumour Neoantigens Revenue Market Share by Manufacturers (2024-2024)
2.3 Global Tumour Neoantigens Average Price by Manufacturers (2024-2024)
2.4 Global Tumour Neoantigens Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Tumour Neoantigens, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Tumour Neoantigens, Product Type & Application
2.7 Tumour Neoantigens Market Competitive Situation and Trends
2.7.1 Tumour Neoantigens Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Tumour Neoantigens Players Market Share by Revenue
2.7.3 Global Tumour Neoantigens Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Tumour Neoantigens Retrospective Market Scenario by Region
3.1 Global Tumour Neoantigens Market Size by Region: 2024 Versus 2022 Versus 2034
3.2 Global Tumour Neoantigens Global Tumour Neoantigens Sales by Region: 2024-2034
3.2.1 Global Tumour Neoantigens Sales by Region: 2024-2024
3.2.2 Global Tumour Neoantigens Sales by Region: 2024-2034
3.3 Global Tumour Neoantigens Global Tumour Neoantigens Revenue by Region: 2024-2034
3.3.1 Global Tumour Neoantigens Revenue by Region: 2024-2024
3.3.2 Global Tumour Neoantigens Revenue by Region: 2024-2034
3.4 North America Tumour Neoantigens Market Facts & Figures by Country
3.4.1 North America Tumour Neoantigens Market Size by Country: 2024 VS 2022 VS 2034
3.4.2 North America Tumour Neoantigens Sales by Country (2024-2034)
3.4.3 North America Tumour Neoantigens Revenue by Country (2024-2034)
3.4.4 United States
3.4.5 Canada
3.5 Europe Tumour Neoantigens Market Facts & Figures by Country
3.5.1 Europe Tumour Neoantigens Market Size by Country: 2024 VS 2022 VS 2034
3.5.2 Europe Tumour Neoantigens Sales by Country (2024-2034)
3.5.3 Europe Tumour Neoantigens Revenue by Country (2024-2034)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Tumour Neoantigens Market Facts & Figures by Country
3.6.1 Asia Pacific Tumour Neoantigens Market Size by Country: 2024 VS 2022 VS 2034
3.6.2 Asia Pacific Tumour Neoantigens Sales by Country (2024-2034)
3.6.3 Asia Pacific Tumour Neoantigens Revenue by Country (2024-2034)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Tumour Neoantigens Market Facts & Figures by Country
3.7.1 Latin America Tumour Neoantigens Market Size by Country: 2024 VS 2022 VS 2034
3.7.2 Latin America Tumour Neoantigens Sales by Country (2024-2034)
3.7.3 Latin America Tumour Neoantigens Revenue by Country (2024-2034)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Tumour Neoantigens Market Facts & Figures by Country
3.8.1 Middle East and Africa Tumour Neoantigens Market Size by Country: 2024 VS 2022 VS 2034
3.8.2 Middle East and Africa Tumour Neoantigens Sales by Country (2024-2034)
3.8.3 Middle East and Africa Tumour Neoantigens Revenue by Country (2024-2034)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Tumour Neoantigens Sales by Type (2024-2034)
4.1.1 Global Tumour Neoantigens Sales by Type (2024-2024)
4.1.2 Global Tumour Neoantigens Sales by Type (2024-2034)
4.1.3 Global Tumour Neoantigens Sales Market Share by Type (2024-2034)
4.2 Global Tumour Neoantigens Revenue by Type (2024-2034)
4.2.1 Global Tumour Neoantigens Revenue by Type (2024-2024)
4.2.2 Global Tumour Neoantigens Revenue by Type (2024-2034)
4.2.3 Global Tumour Neoantigens Revenue Market Share by Type (2024-2034)
4.3 Global Tumour Neoantigens Price by Type (2024-2034)
5 Segment by Application
5.1 Global Tumour Neoantigens Sales by Application (2024-2034)
5.1.1 Global Tumour Neoantigens Sales by Application (2024-2024)
5.1.2 Global Tumour Neoantigens Sales by Application (2024-2034)
5.1.3 Global Tumour Neoantigens Sales Market Share by Application (2024-2034)
5.2 Global Tumour Neoantigens Revenue by Application (2024-2034)
5.2.1 Global Tumour Neoantigens Revenue by Application (2024-2024)
5.2.2 Global Tumour Neoantigens Revenue by Application (2024-2034)
5.2.3 Global Tumour Neoantigens Revenue Market Share by Application (2024-2034)
5.3 Global Tumour Neoantigens Price by Application (2024-2034)
6 Key Companies Profiled
6.1 Achilles Therapeutics plc
6.1.1 Achilles Therapeutics plc Corporation Information
6.1.2 Achilles Therapeutics plc Description and Business Overview
6.1.3 Achilles Therapeutics plc Tumour Neoantigens Sales, Revenue and Gross Margin (2024-2024)
6.1.4 Achilles Therapeutics plc Tumour Neoantigens Product Portfolio
6.1.5 Achilles Therapeutics plc Recent Developments/Updates
6.2 Advaxis Immunotherapies
6.2.1 Advaxis Immunotherapies Corporation Information
6.2.2 Advaxis Immunotherapies Description and Business Overview
6.2.3 Advaxis Immunotherapies Tumour Neoantigens Sales, Revenue and Gross Margin (2024-2024)
6.2.4 Advaxis Immunotherapies Tumour Neoantigens Product Portfolio
6.2.5 Advaxis Immunotherapies Recent Developments/Updates
6.3 Genocea
6.3.1 Genocea Corporation Information
6.3.2 Genocea Description and Business Overview
6.3.3 Genocea Tumour Neoantigens Sales, Revenue and Gross Margin (2024-2024)
6.3.4 Genocea Tumour Neoantigens Product Portfolio
6.3.5 Genocea Recent Developments/Updates
6.4 Gradalis, Inc
6.4.1 Gradalis, Inc Corporation Information
6.4.2 Gradalis, Inc Description and Business Overview
6.4.3 Gradalis, Inc Tumour Neoantigens Sales, Revenue and Gross Margin (2024-2024)
6.4.4 Gradalis, Inc Tumour Neoantigens Product Portfolio
6.4.5 Gradalis, Inc Recent Developments/Updates
6.5 Gritstone bio
6.5.1 Gritstone bio Corporation Information
6.5.2 Gritstone bio Description and Business Overview
6.5.3 Gritstone bio Tumour Neoantigens Sales, Revenue and Gross Margin (2024-2024)
6.5.4 Gritstone bio Tumour Neoantigens Product Portfolio
6.5.5 Gritstone bio Recent Developments/Updates
6.6 Iovance Biotherapetics Inc
6.6.1 Iovance Biotherapetics Inc Corporation Information
6.6.2 Iovance Biotherapetics Inc Description and Business Overview
6.6.3 Iovance Biotherapetics Inc Tumour Neoantigens Sales, Revenue and Gross Margin (2024-2024)
6.6.4 Iovance Biotherapetics Inc Tumour Neoantigens Product Portfolio
6.6.5 Iovance Biotherapetics Inc Recent Developments/Updates
6.7 Medigene AG
6.6.1 Medigene AG Corporation Information
6.6.2 Medigene AG Description and Business Overview
6.6.3 Medigene AG Tumour Neoantigens Sales, Revenue and Gross Margin (2024-2024)
6.4.4 Medigene AG Tumour Neoantigens Product Portfolio
6.7.5 Medigene AG Recent Developments/Updates
6.8 BioNTech SE
6.8.1 BioNTech SE Corporation Information
6.8.2 BioNTech SE Description and Business Overview
6.8.3 BioNTech SE Tumour Neoantigens Sales, Revenue and Gross Margin (2024-2024)
6.8.4 BioNTech SE Tumour Neoantigens Product Portfolio
6.8.5 BioNTech SE Recent Developments/Updates
6.9 Lilly
6.9.1 Lilly Corporation Information
6.9.2 Lilly Description and Business Overview
6.9.3 Lilly Tumour Neoantigens Sales, Revenue and Gross Margin (2024-2024)
6.9.4 Lilly Tumour Neoantigens Product Portfolio
6.9.5 Lilly Recent Developments/Updates
6.10 Scicomvisuals
6.10.1 Scicomvisuals Corporation Information
6.10.2 Scicomvisuals Description and Business Overview
6.10.3 Scicomvisuals Tumour Neoantigens Sales, Revenue and Gross Margin (2024-2024)
6.10.4 Scicomvisuals Tumour Neoantigens Product Portfolio
6.10.5 Scicomvisuals Recent Developments/Updates
6.11 Moderna, Inc
6.11.1 Moderna, Inc Corporation Information
6.11.2 Moderna, Inc Tumour Neoantigens Description and Business Overview
6.11.3 Moderna, Inc Tumour Neoantigens Sales, Revenue and Gross Margin (2024-2024)
6.11.4 Moderna, Inc Tumour Neoantigens Product Portfolio
6.11.5 Moderna, Inc Recent Developments/Updates
6.12 F. Hoffmann-La Roche Ltd
6.12.1 F. Hoffmann-La Roche Ltd Corporation Information
6.12.2 F. Hoffmann-La Roche Ltd Tumour Neoantigens Description and Business Overview
6.12.3 F. Hoffmann-La Roche Ltd Tumour Neoantigens Sales, Revenue and Gross Margin (2024-2024)
6.12.4 F. Hoffmann-La Roche Ltd Tumour Neoantigens Product Portfolio
6.12.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
6.13 Merck KGaA
6.13.1 Merck KGaA Corporation Information
6.13.2 Merck KGaA Tumour Neoantigens Description and Business Overview
6.13.3 Merck KGaA Tumour Neoantigens Sales, Revenue and Gross Margin (2024-2024)
6.13.4 Merck KGaA Tumour Neoantigens Product Portfolio
6.13.5 Merck KGaA Recent Developments/Updates
6.14 Sun Pharmaceutical Industries Ltd
6.14.1 Sun Pharmaceutical Industries Ltd Corporation Information
6.14.2 Sun Pharmaceutical Industries Ltd Tumour Neoantigens Description and Business Overview
6.14.3 Sun Pharmaceutical Industries Ltd Tumour Neoantigens Sales, Revenue and Gross Margin (2024-2024)
6.14.4 Sun Pharmaceutical Industries Ltd Tumour Neoantigens Product Portfolio
6.14.5 Sun Pharmaceutical Industries Ltd Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Tumour Neoantigens Industry Chain Analysis
7.2 Tumour Neoantigens Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Tumour Neoantigens Production Mode & Process
7.4 Tumour Neoantigens Sales and Marketing
7.4.1 Tumour Neoantigens Sales Channels
7.4.2 Tumour Neoantigens Distributors
7.5 Tumour Neoantigens Customers
8 Tumour Neoantigens Market Dynamics
8.1 Tumour Neoantigens Industry Trends
8.2 Tumour Neoantigens Market Drivers
8.3 Tumour Neoantigens Market Challenges
8.4 Tumour Neoantigens Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Tumour Neoantigens Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Tumour Neoantigens Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Tumour Neoantigens Market Competitive Situation by Manufacturers in 2022
Table 4. Global Tumour Neoantigens Sales (K Units) of Key Manufacturers (2024-2024)
Table 5. Global Tumour Neoantigens Sales Market Share by Manufacturers (2024-2024)
Table 6. Global Tumour Neoantigens Revenue (US$ Million) by Manufacturers (2024-2024)
Table 7. Global Tumour Neoantigens Revenue Share by Manufacturers (2024-2024)
Table 8. Global Market Tumour Neoantigens Average Price (US$/Unit) of Key Manufacturers (2024-2024)
Table 9. Global Key Players of Tumour Neoantigens, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Tumour Neoantigens, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Tumour Neoantigens, Product Type & Application
Table 12. Global Key Manufacturers of Tumour Neoantigens, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Tumour Neoantigens by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumour Neoantigens as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Tumour Neoantigens Market Size by Region (US$ Million): 2024 VS 2022 VS 2034
Table 17. Global Tumour Neoantigens Sales by Region (2024-2024) & (K Units)
Table 18. Global Tumour Neoantigens Sales Market Share by Region (2024-2024)
Table 19. Global Tumour Neoantigens Sales by Region (2024-2034) & (K Units)
Table 20. Global Tumour Neoantigens Sales Market Share by Region (2024-2034)
Table 21. Global Tumour Neoantigens Revenue by Region (2024-2024) & (US$ Million)
Table 22. Global Tumour Neoantigens Revenue Market Share by Region (2024-2024)
Table 23. Global Tumour Neoantigens Revenue by Region (2024-2034) & (US$ Million)
Table 24. Global Tumour Neoantigens Revenue Market Share by Region (2024-2034)
Table 25. North America Tumour Neoantigens Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 26. North America Tumour Neoantigens Sales by Country (2024-2024) & (K Units)
Table 27. North America Tumour Neoantigens Sales by Country (2024-2034) & (K Units)
Table 28. North America Tumour Neoantigens Revenue by Country (2024-2024) & (US$ Million)
Table 29. North America Tumour Neoantigens Revenue by Country (2024-2034) & (US$ Million)
Table 30. Europe Tumour Neoantigens Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 31. Europe Tumour Neoantigens Sales by Country (2024-2024) & (K Units)
Table 32. Europe Tumour Neoantigens Sales by Country (2024-2034) & (K Units)
Table 33. Europe Tumour Neoantigens Revenue by Country (2024-2024) & (US$ Million)
Table 34. Europe Tumour Neoantigens Revenue by Country (2024-2034) & (US$ Million)
Table 35. Asia Pacific Tumour Neoantigens Revenue by Region: 2024 VS 2022 VS 2034 (US$ Million)
Table 36. Asia Pacific Tumour Neoantigens Sales by Region (2024-2024) & (K Units)
Table 37. Asia Pacific Tumour Neoantigens Sales by Region (2024-2034) & (K Units)
Table 38. Asia Pacific Tumour Neoantigens Revenue by Region (2024-2024) & (US$ Million)
Table 39. Asia Pacific Tumour Neoantigens Revenue by Region (2024-2034) & (US$ Million)
Table 40. Latin America Tumour Neoantigens Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 41. Latin America Tumour Neoantigens Sales by Country (2024-2024) & (K Units)
Table 42. Latin America Tumour Neoantigens Sales by Country (2024-2034) & (K Units)
Table 43. Latin America Tumour Neoantigens Revenue by Country (2024-2024) & (US$ Million)
Table 44. Latin America Tumour Neoantigens Revenue by Country (2024-2034) & (US$ Million)
Table 45. Middle East & Africa Tumour Neoantigens Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 46. Middle East & Africa Tumour Neoantigens Sales by Country (2024-2024) & (K Units)
Table 47. Middle East & Africa Tumour Neoantigens Sales by Country (2024-2034) & (K Units)
Table 48. Middle East & Africa Tumour Neoantigens Revenue by Country (2024-2024) & (US$ Million)
Table 49. Middle East & Africa Tumour Neoantigens Revenue by Country (2024-2034) & (US$ Million)
Table 50. Global Tumour Neoantigens Sales (K Units) by Type (2024-2024)
Table 51. Global Tumour Neoantigens Sales (K Units) by Type (2024-2034)
Table 52. Global Tumour Neoantigens Sales Market Share by Type (2024-2024)
Table 53. Global Tumour Neoantigens Sales Market Share by Type (2024-2034)
Table 54. Global Tumour Neoantigens Revenue (US$ Million) by Type (2024-2024)
Table 55. Global Tumour Neoantigens Revenue (US$ Million) by Type (2024-2034)
Table 56. Global Tumour Neoantigens Revenue Market Share by Type (2024-2024)
Table 57. Global Tumour Neoantigens Revenue Market Share by Type (2024-2034)
Table 58. Global Tumour Neoantigens Price (US$/Unit) by Type (2024-2024)
Table 59. Global Tumour Neoantigens Price (US$/Unit) by Type (2024-2034)
Table 60. Global Tumour Neoantigens Sales (K Units) by Application (2024-2024)
Table 61. Global Tumour Neoantigens Sales (K Units) by Application (2024-2034)
Table 62. Global Tumour Neoantigens Sales Market Share by Application (2024-2024)
Table 63. Global Tumour Neoantigens Sales Market Share by Application (2024-2034)
Table 64. Global Tumour Neoantigens Revenue (US$ Million) by Application (2024-2024)
Table 65. Global Tumour Neoantigens Revenue (US$ Million) by Application (2024-2034)
Table 66. Global Tumour Neoantigens Revenue Market Share by Application (2024-2024)
Table 67. Global Tumour Neoantigens Revenue Market Share by Application (2024-2034)
Table 68. Global Tumour Neoantigens Price (US$/Unit) by Application (2024-2024)
Table 69. Global Tumour Neoantigens Price (US$/Unit) by Application (2024-2034)
Table 70. Achilles Therapeutics plc Corporation Information
Table 71. Achilles Therapeutics plc Description and Business Overview
Table 72. Achilles Therapeutics plc Tumour Neoantigens Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 73. Achilles Therapeutics plc Tumour Neoantigens Product
Table 74. Achilles Therapeutics plc Recent Developments/Updates
Table 75. Advaxis Immunotherapies Corporation Information
Table 76. Advaxis Immunotherapies Description and Business Overview
Table 77. Advaxis Immunotherapies Tumour Neoantigens Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 78. Advaxis Immunotherapies Tumour Neoantigens Product
Table 79. Advaxis Immunotherapies Recent Developments/Updates
Table 80. Genocea Corporation Information
Table 81. Genocea Description and Business Overview
Table 82. Genocea Tumour Neoantigens Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 83. Genocea Tumour Neoantigens Product
Table 84. Genocea Recent Developments/Updates
Table 85. Gradalis, Inc Corporation Information
Table 86. Gradalis, Inc Description and Business Overview
Table 87. Gradalis, Inc Tumour Neoantigens Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 88. Gradalis, Inc Tumour Neoantigens Product
Table 89. Gradalis, Inc Recent Developments/Updates
Table 90. Gritstone bio Corporation Information
Table 91. Gritstone bio Description and Business Overview
Table 92. Gritstone bio Tumour Neoantigens Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 93. Gritstone bio Tumour Neoantigens Product
Table 94. Gritstone bio Recent Developments/Updates
Table 95. Iovance Biotherapetics Inc Corporation Information
Table 96. Iovance Biotherapetics Inc Description and Business Overview
Table 97. Iovance Biotherapetics Inc Tumour Neoantigens Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 98. Iovance Biotherapetics Inc Tumour Neoantigens Product
Table 99. Iovance Biotherapetics Inc Recent Developments/Updates
Table 100. Medigene AG Corporation Information
Table 101. Medigene AG Description and Business Overview
Table 102. Medigene AG Tumour Neoantigens Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 103. Medigene AG Tumour Neoantigens Product
Table 104. Medigene AG Recent Developments/Updates
Table 105. BioNTech SE Corporation Information
Table 106. BioNTech SE Description and Business Overview
Table 107. BioNTech SE Tumour Neoantigens Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 108. BioNTech SE Tumour Neoantigens Product
Table 109. BioNTech SE Recent Developments/Updates
Table 110. Lilly Corporation Information
Table 111. Lilly Description and Business Overview
Table 112. Lilly Tumour Neoantigens Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 113. Lilly Tumour Neoantigens Product
Table 114. Lilly Recent Developments/Updates
Table 115. Scicomvisuals Corporation Information
Table 116. Scicomvisuals Description and Business Overview
Table 117. Scicomvisuals Tumour Neoantigens Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 118. Scicomvisuals Tumour Neoantigens Product
Table 119. Scicomvisuals Recent Developments/Updates
Table 120. Moderna, Inc Corporation Information
Table 121. Moderna, Inc Description and Business Overview
Table 122. Moderna, Inc Tumour Neoantigens Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 123. Moderna, Inc Tumour Neoantigens Product
Table 124. Moderna, Inc Recent Developments/Updates
Table 125. F. Hoffmann-La Roche Ltd Corporation Information
Table 126. F. Hoffmann-La Roche Ltd Description and Business Overview
Table 127. F. Hoffmann-La Roche Ltd Tumour Neoantigens Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 128. F. Hoffmann-La Roche Ltd Tumour Neoantigens Product
Table 129. F. Hoffmann-La Roche Ltd Recent Developments/Updates
Table 130. Merck KGaA Corporation Information
Table 131. Merck KGaA Description and Business Overview
Table 132. Merck KGaA Tumour Neoantigens Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 133. Merck KGaA Tumour Neoantigens Product
Table 134. Merck KGaA Recent Developments/Updates
Table 135. Sun Pharmaceutical Industries Ltd Corporation Information
Table 136. Sun Pharmaceutical Industries Ltd Description and Business Overview
Table 137. Sun Pharmaceutical Industries Ltd Tumour Neoantigens Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 138. Sun Pharmaceutical Industries Ltd Tumour Neoantigens Product
Table 139. Sun Pharmaceutical Industries Ltd Recent Developments/Updates
Table 140. Key Raw Materials Lists
Table 141. Raw Materials Key Suppliers Lists
Table 142. Tumour Neoantigens Distributors List
Table 143. Tumour Neoantigens Customers List
Table 144. Tumour Neoantigens Market Trends
Table 145. Tumour Neoantigens Market Drivers
Table 146. Tumour Neoantigens Market Challenges
Table 147. Tumour Neoantigens Market Restraints
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Tumour Neoantigens
Figure 2. Global Tumour Neoantigens Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Tumour Neoantigens Market Share by Type in 2022 & 2034
Figure 4. Common Neoantigens Product Picture
Figure 5. Individualized Neoantigens Product Picture
Figure 6. Global Tumour Neoantigens Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 7. Global Tumour Neoantigens Market Share by Application in 2022 & 2034
Figure 8. T Cell Adoptive Therapy
Figure 9. DC Therapy
Figure 10. Therapeutic Vaccines
Figure 11. Other
Figure 12. Global Tumour Neoantigens Revenue, (US$ Million), 2024 VS 2022 VS 2034
Figure 13. Global Tumour Neoantigens Market Size (2024-2034) & (US$ Million)
Figure 14. Global Tumour Neoantigens Sales (2024-2034) & (K Units)
Figure 15. Global Tumour Neoantigens Average Price (US$/Unit) & (2024-2034)
Figure 16. Tumour Neoantigens Report Years Considered
Figure 17. Tumour Neoantigens Sales Share by Manufacturers in 2022
Figure 18. Global Tumour Neoantigens Revenue Share by Manufacturers in 2022
Figure 19. The Global 5 and 10 Largest Tumour Neoantigens Players: Market Share by Revenue in 2022
Figure 20. Tumour Neoantigens Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024 VS 2022
Figure 21. Global Tumour Neoantigens Market Size by Region (US$ Million): 2024 VS 2022 VS 2034
Figure 22. North America Tumour Neoantigens Sales Market Share by Country (2024-2034)
Figure 23. North America Tumour Neoantigens Revenue Market Share by Country (2024-2034)
Figure 24. United States Tumour Neoantigens Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 25. Canada Tumour Neoantigens Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 26. Europe Tumour Neoantigens Sales Market Share by Country (2024-2034)
Figure 27. Europe Tumour Neoantigens Revenue Market Share by Country (2024-2034)
Figure 28. Germany Tumour Neoantigens Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 29. France Tumour Neoantigens Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 30. U.K. Tumour Neoantigens Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 31. Italy Tumour Neoantigens Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 32. Russia Tumour Neoantigens Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 33. Asia Pacific Tumour Neoantigens Sales Market Share by Region (2024-2034)
Figure 34. Asia Pacific Tumour Neoantigens Revenue Market Share by Region (2024-2034)
Figure 35. China Tumour Neoantigens Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 36. Japan Tumour Neoantigens Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 37. South Korea Tumour Neoantigens Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 38. India Tumour Neoantigens Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 39. Australia Tumour Neoantigens Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 40. China Taiwan Tumour Neoantigens Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 41. Southeast Asia Tumour Neoantigens Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 42. Latin America Tumour Neoantigens Sales Market Share by Country (2024-2034)
Figure 43. Latin America Tumour Neoantigens Revenue Market Share by Country (2024-2034)
Figure 44. Mexico Tumour Neoantigens Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 45. Brazil Tumour Neoantigens Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 46. Argentina Tumour Neoantigens Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 47. Middle East & Africa Tumour Neoantigens Sales Market Share by Country (2024-2034)
Figure 48. Middle East & Africa Tumour Neoantigens Revenue Market Share by Country (2024-2034)
Figure 49. Turkey Tumour Neoantigens Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 50. Saudi Arabia Tumour Neoantigens Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 51. UAE Tumour Neoantigens Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 52. Global Sales Market Share of Tumour Neoantigens by Type (2024-2034)
Figure 53. Global Revenue Market Share of Tumour Neoantigens by Type (2024-2034)
Figure 54. Global Tumour Neoantigens Price (US$/Unit) by Type (2024-2034)
Figure 55. Global Sales Market Share of Tumour Neoantigens by Application (2024-2034)
Figure 56. Global Revenue Market Share of Tumour Neoantigens by Application (2024-2034)
Figure 57. Global Tumour Neoantigens Price (US$/Unit) by Application (2024-2034)
Figure 58. Tumour Neoantigens Value Chain
Figure 59. Tumour Neoantigens Production Process
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Distributors Profiles
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed